ℹTo save a PDF: Click "Print", and select "Print to PDF"
COMPERA 2.0: 4-Strata Risk Assessment
The 2022 ESC/ERS Treatment Guidelines recommend using 4-strata risk stratification in follow-up visits every 3-6 months. All values are required to calculate score. 1 year transplant-free mortality risk is based on average points assigned.
Risk Status (1 Yr Survival Rates) Points Assigned
Low (98.5%) 1
Intermediate-Low (97.2%) 2
Intermediate-High (91.3%) 3
High (78%) 4
Intermediate- Low Risk
Intermediate- High Risk
All use subject to terms and conditions at www.unither.com/terms.html
References:1.Boucly A, Weatherald J, Salvale L, et al. External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. Eur Respir J 2022; 59:2102419 [DOI: 10.1183/13993003.02419-2021].